Insulet Financial Model
Medical Devices Company Financials Example (Free Excel Download)
Insulet Corporation is an innovative medical device company that develops, manufactures, and sells the Omnipod system, a continuous and tubeless automated insulin delivery (AID) system for people with insulin-requiring diabetes.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and scenario analysis framework to determine if Insulet's high-growth trajectory and operating margin expansion justify its premium market valuation amidst intensifying competition in the automated insulin delivery market.
Insulet Corporation is an innovative medical device company that develops, manufactures, and sells the Omnipod system, a continuous and tubeless automated insulin delivery (AID) system for people with insulin-requiring diabetes. The company operates a "razor and razorblade" business model, generating recurring revenue through the ongoing sale of disposable pods via the pharmacy channel.
Business segments include:
- U.S. Omnipod (approximately 70% of total revenue)
- International Omnipod (approximately 28% of total revenue)
- Drug Delivery (approximately 2% of total revenue)
The company operates globally, with the United States and Europe serving as its primary markets. Insulet holds a dominant competitive position as the global leader in tubeless insulin pumps, consistently ranking first in new customer starts. Key competitors include Tandem Diabetes Care, Medtronic, and Beta Bionics. Recent major events include the 2025 FDA clearance and launch of Omnipod 5 for Type 2 diabetes, which significantly expanded the company's total addressable market, and the achievement of $2.7 billion in full-year 2025 revenue.
The downloadable Insulet financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsInsulet financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.04B | $1.06B | $1.70B | $2.07B | $2.71B |
| Gross profit | $752.1M | $805.6M | $1.16B | $1.45B | $1.94B |
| Operating income | $126.0M | $37.6M | $220.1M | $308.9M | $473.8M |
| Net income | $16.8M | $4.6M | $206.3M | $418.3M | $247.1M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Insulet
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
U.S. Omnipod
- Segment name: U.S. Omnipod
- Revenue driver formula: Estimated Active U.S. Users x Annual Pod Consumption per User x Net Price per Pod
- Historical growth rate: 20% to 28% year-over-year growth (27.2% in 2025)
- Key growth levers and headwinds: Levers include the expansion into the Type 2 diabetes market, integration with continuous glucose monitors (Dexcom and Abbott), and transitions from multiple daily injections. Headwinds include the rising adoption of GLP-1 drugs which may delay insulin dependence, and competitive AID product launches.
- Pricing dynamics: Contractual pricing negotiated with pharmacy benefit managers (PBMs) and health insurers. The pharmacy channel model provides a pay-as-you-go structure rather than a large upfront durable pump cost.
- Revenue recognition notes: Revenue is recognised upon transfer of control to distributors or directly to patients.
- Seasonality: The fourth quarter is historically the strongest due to U.S. healthcare deductible resets and end-of-year purchasing dynamics.
International Omnipod
- Segment name: International Omnipod
- Revenue driver formula: Estimated Active International Users x Annual Pod Consumption per User x Net Price per Pod (adjusted for FX)
- Historical growth rate: 25% to 45% year-over-year growth (44.1% in 2025)
- Key growth levers and headwinds: Levers include geographic expansion (launched in nine new markets in 2025) and securing reimbursement in European countries. Headwinds include foreign exchange volatility and varying international reimbursement timelines.
- Pricing dynamics: Regulated and negotiated pricing with national health systems.
- Revenue recognition notes: Similar to the U.S., recognised upon delivery to distributors or patients.
- Seasonality: Less pronounced than the U.S., but generally follows a steady sequential growth pattern.
Drug Delivery
- Segment name: Drug Delivery
- Revenue driver formula: Partner Contract Volume x Contractual Unit Price
- Historical growth rate: Highly volatile, currently contracting (declined to $34.1 million in 2025, expected to drop 50% in 2026)
- Key growth levers and headwinds: Driven by specific pharmaceutical partnerships for non-insulin subcutaneous drug delivery. The segment is currently facing severe headwinds as legacy contracts wind down.
- Pricing dynamics: Fixed contractual pricing based on custom manufacturing agreements.
- Revenue recognition notes: Recognised upon shipment to pharmaceutical partners.
- Seasonality: Lumpy and dependent on partner ordering schedules.
Cost Structure
Variable Costs / COGS
- COGS primarily consists of raw materials, electronic components, batteries, and direct labour associated with the highly automated manufacturing of disposable pods in the U.S. and China.
- Gross margin range over the last 5 years has been 67% to 72.5% (reaching 71.6% for the full year 2025).
- Key input costs include plastics, microelectronics, and freight.
- COGS scales with volume, but the company benefits from significant operating leverage and unit cost reductions as its automated manufacturing lines reach full capacity utilisation.
Operating Expenses
- R&D: Typically runs at 8% to 10% of revenue. It covers software development, algorithm improvements for automated insulin delivery, and integration with third-party continuous glucose monitors.
- SG&A: The largest operating expense, typically 40% to 45% of revenue. It is heavily driven by the expansion of the direct sales force (especially for the Type 2 diabetes market rollout) and direct-to-consumer marketing campaigns.
- Depreciation & Amortisation: Typically 4% to 6% of revenue, heavily weighted towards tangible assets (manufacturing equipment).
- Stock-Based Compensation: Runs at approximately 3% to 4% of revenue.
- Restructuring / one-time charges: Infrequent, though the company occasionally records medical device correction charges or legal settlements.
Margin Profile
- Gross margin has expanded from the high 60s to 71.6% in 2025.
- Operating margin has expanded significantly, reaching 17.5% in 2025 (up 260 basis points year-over-year).
- Net margin sits in the 9% to 15% range, impacted by convertible debt interest and tax valuation allowance releases.
- Margins are expanding due to manufacturing efficiencies, a shift to the higher-margin pharmacy channel, and operating leverage on SG&A as the revenue base scales.
Balance Sheet Structure
- Total assets are approximately $3.5 billion, with current assets making up roughly $1.9 billion.
- Key asset categories include cash and cash equivalents ($716.1 million at the end of 2025), accounts receivable from pharmacy distributors, and inventory (finished pods and components).
- Goodwill & intangibles represent a small percentage of total assets, as Insulet relies primarily on organic growth rather than transformational M&A.
- Working capital profile:
- Days Sales Outstanding (DSO): 45 to 55 days.
- Days Inventory Outstanding (DIO): 100 to 120 days (the company holds buffer stock to ensure patients do not run out of critical medical supplies).
- Days Payable Outstanding (DPO): 30 to 45 days.
- Net working capital as a percentage of revenue is typically positive (15% to 20%).
- PP&E consists heavily of highly automated manufacturing equipment at facilities in Massachusetts and China.
- Right-of-use assets are material but manageable, relating primarily to manufacturing and corporate facility leases.
Capital Expenditure & Investment
- Capex as a percentage of revenue typically ranges from 6% to 9% ($191.6 million in 2025, roughly 7.1% of revenue).
- The split is heavily weighted towards growth capex (approximately 70%) to build new automated manufacturing lines to support 20%+ annual volume growth.
- Major capex programmes include the continuous expansion of the U.S. manufacturing facility to localise production and reduce freight costs.
- Capitalised software costs are present but represent a minor portion of total capex.
- Insulet is an organic grower. M&A activity is limited to small, bolt-on technology acquisitions (such as algorithm developers).
Debt & Capital Structure
- Total debt is approximately $1.4 billion, consisting entirely of Convertible Senior Notes.
- Net debt is approximately $700 million.
- Debt/EBITDA ratio is currently below 2.0x and declining as profitability scales.
- The company does not have a traditional syndicated term loan or revolving credit facility reliance, funding operations through cash flow and convertible notes.
- Interest rate profile is fixed via the convertible notes, resulting in a low cash interest burden but requiring non-cash interest expense amortisation.
- The company has an active share repurchase programme, recently expanding its authorisation to $475 million, with $300 million planned for execution in the first quarter of 2026.
- Insulet does not pay a dividend, reinvesting cash flow into growth and share repurchases.
Cash Flow Characteristics
- Operating cash flow conversion (OCF / Net Income) is exceptionally strong, typically ranging from 1.5x to 2.0x ($569.3 million OCF in 2025).
- Free cash flow margin (FCF / Revenue) ranges from 10% to 14% ($377.7 million FCF in 2025, a 14% margin).
- Major non-cash items bridging net income to OCF include depreciation, stock-based compensation, and the amortisation of debt discount on convertible notes.
- Working capital is a use of cash due to the need to build inventory to support rapid revenue growth.
- Capex intensity is moderate but necessary to support the physical manufacturing of pods.
Sheet Structure
- Assumptions: Hardcoded inputs for revenue growth by segment, margin targets, working capital days, capex percentage, and share repurchases.
- Scenarios: Toggle for Base, Bull, and Bear cases affecting AID market penetration and GLP-1 impact.
- Revenue Build: Detailed build for U.S. Omnipod, International Omnipod, and Drug Delivery. Includes volume and pricing assumptions.
- Income Statement: Consolidated view mirroring the 10-K. Revenue lines match the three segments. Includes COGS, Gross Profit, R&D, SG&A, Operating Income, Interest Expense, and Net Income.
- Balance Sheet: Standard assets, liabilities, and equity. Breaks out Cash, Accounts Receivable, Inventory, PP&E, Convertible Debt, and Retained Earnings.
- Cash Flow Statement: Operating, Investing, and Financing cash flows. Links directly from the Income Statement and Balance Sheet changes.
- Debt Schedule: Tracks the Convertible Senior Notes, interest expense (cash vs non-cash), and maturity schedule.
- Working Capital: Calculates Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO assumptions.
- PP&E & Capex: Tracks gross PP&E, capital expenditures, depreciation expense, and net PP&E.
- DCF Valuation: Unlevered free cash flow calculation, WACC assumptions, terminal value, and implied share price.
Key Financial Relationships
- U.S. Omnipod Revenue = Prior Year U.S. Omnipod Revenue x (1 + U.S. Omnipod Growth Rate)
- International Omnipod Revenue = Prior Year International Omnipod Revenue x (1 + International Omnipod Growth Rate)
- Drug Delivery Revenue = Prior Year Drug Delivery Revenue x (1 + Drug Delivery Growth Rate)
- Total Revenue = U.S. Omnipod Revenue + International Omnipod Revenue + Drug Delivery Revenue
- COGS = Total Revenue x (1 - Gross Margin Percentage)
- Gross Profit = Total Revenue - COGS
- R&D Expense = Total Revenue x R&D Margin Percentage
- SG&A Expense = Total Revenue x SG&A Margin Percentage
- Operating Income = Gross Profit - R&D Expense - SG&A Expense
- Accounts Receivable = (Total Revenue / 365) x DSO
- Inventory = (COGS / 365) x DIO
- Accounts Payable = (COGS / 365) x DPO
- Capital Expenditures = Total Revenue x Capex Percentage
- Free Cash Flow = Operating Cash Flow - Capital Expenditures
- Diluted Shares Outstanding = Base Shares - (Share Repurchase Amount / Average Share Price) + Options Dilution
Cross-Sheet Dependencies
- The Assumptions sheet dictates the growth rates and margin profiles used in the Revenue Build and Income Statement.
- The Revenue Build feeds the top line of the Income Statement and drives the Accounts Receivable calculation on the Working Capital sheet.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- The Working Capital sheet calculates the changes in operating assets and liabilities, which feed into the Operating Cash Flow section of the Cash Flow Statement.
- The PP&E & Capex sheet calculates depreciation (feeding the Income Statement and Cash Flow Statement) and ending PP&E (feeding the Balance Sheet).
- The Debt Schedule calculates interest expense for the Income Statement and ending debt balances for the Balance Sheet.
- The Cash Flow Statement calculates the net change in cash, which links to the Cash line on the Balance Sheet to ensure it balances. A circularity exists if interest income on cash balances is modelled, requiring an iterative calculation toggle.
Sign Convention
- Revenues, margins, and asset balances are entered and displayed as positive numbers.
- Expenses (COGS, R&D, SG&A, Interest Expense) on the Income Statement are entered as negative numbers so that Gross Profit and Operating Income can be calculated using simple sum formulas.
- On the Cash Flow Statement, cash inflows are positive and cash outflows (such as capital expenditures and share repurchases) are negative.
- Contra-asset accounts (like Accumulated Depreciation) are displayed as negative numbers.
Things Most Likely to Go Wrong
- Failing to model the Drug Delivery segment's sharp contraction correctly. The company expects this segment to decline by 50% in 2026; applying a historical growth rate will overstate total revenue.
- Ignoring the impact of constant currency adjustments. International Omnipod revenue growth is heavily influenced by FX; the model must distinguish between reported and constant currency growth.
- Misunderstanding the pharmacy channel stocking dynamics. Wholesale distributors occasionally alter inventory levels (e.g., a $30 million benefit in Q4 2023), which can distort year-over-year quarterly growth rates.
- Overestimating operating margin expansion. While management targets 100 basis points of annual expansion, aggressive SG&A investments for the Type 2 diabetes launch could compress margins in the near term.
- Mishandling the convertible debt accounting. The non-cash amortisation of the debt discount must be added back to the Cash Flow Statement, and the potential share dilution from the conversion feature must be factored into the EPS calculation.
- Applying a generic tax rate. Insulet's GAAP net income in 2024 was artificially inflated by a massive tax valuation allowance release; the model must use a normalised cash tax rate for forward projections.
- Underestimating share count reduction. The company has aggressively expanded its share repurchase programme ($475 million authorisation), which will significantly impact EPS calculations.
- Failing to account for seasonality. Q4 is disproportionately large for U.S. revenue; straight-lining annual revenue across four quarters will result in inaccurate quarterly cash flow projections.
Validation Checks
- Gross margin should remain between 70.5% and 73.0% based on management guidance and recent historical performance; flag if outside this band.
- Operating margin should show steady expansion, targeting approximately 18% to 20% in the near term.
- U.S. Omnipod revenue growth should not exceed 25% in the base case without flagging, as market penetration matures.
- Drug Delivery revenue must show a steep decline in the first projected year (approximately 50% drop).
- Capex as a percentage of revenue should remain between 6% and 8%.
- Free cash flow conversion (FCF / Net Income) should remain above 1.0x.
- The Balance Sheet must balance: Total Assets = Total Liabilities + Equity in every period.
- Share count should decrease year-over-year reflecting the $300 million planned repurchase in Q1 2026.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| U.S. Omnipod Revenue Growth | 21.0 | % | Midpoint of management's 2026 guidance (20% - 22%) |
| International Omnipod Revenue Growth | 25.0 | % | Midpoint of management's 2026 guidance (24% - 26%) |
| Drug Delivery Revenue Growth | -50.0 | % | Management guidance for 2026 contraction |
| Gross Margin | 72.0 | % | Slight expansion from 2025 actuals (71.6%) |
| R&D as % of Revenue | 9.0 | % | Historical average required to maintain software/sensor integration |
| SG&A as % of Revenue | 44.5 | % | Required to support Type 2 diabetes sales force expansion |
| Operating Margin | 18.5 | % | Reflects targeted 100 bps annual expansion from 2025 (17.5%) |
| Days Sales Outstanding (DSO) | 50 | Days | Historical average based on pharmacy distributor payment terms |
| Days Inventory Outstanding (DIO) | 110 | Days | Historical average to maintain buffer stock |
| Days Payable Outstanding (DPO) | 40 | Days | Historical average |
| Capex as % of Revenue | 7.0 | % | Aligns with 2025 actuals ($191.6M on $2.7B revenue) |
| Effective Tax Rate | 21.0 | % | Normalised statutory rate excluding valuation allowance noise |
| Share Repurchase (Year 1) | 300.0 | $ Millions | Management stated plan for Q1 2026 execution |
| WACC | 8.5 | % | Standard discount rate for high-growth med-tech |
| Terminal Growth Rate | 3.0 | % | Long-term GDP plus healthcare premium |
Data Sources & Benchmarks
- Filings: SEC EDGAR database for Insulet Corporation (PODD) 10-K and 10-Q filings.
- Investor Relations: Insulet IR website for the Q4 2025 Earnings Release and the 2025 Investor Day Presentation.
- Direct Peers: Tandem Diabetes Care (TNDM), Medtronic (MDT) Diabetes segment, Dexcom (DXCM).
- Industry Data: Seagrove Partners Research for automated insulin delivery market share and penetration rates.
- Consensus Estimates: FactSet or Bloomberg for forward-looking analyst consensus on revenue and EPS.
Sources
- Insulet Corporation Q4 and Full Year 2025 Earnings Release (February 18, 2026) - https://investors.insulet.com
- Insulet Corporation 2025 Investor Day Presentation (November 20, 2025) - https://investors.insulet.com
- Insulet Corporation Q3 2025 Earnings Presentation (November 6, 2025) - https://investors.insulet.com
- Seeking Alpha Earnings Review: Insulet Q4 2025 (February 19, 2026)
Do more with the Insulet model
Frequently asked
What does Insulet Corporation do?+
Insulet Corporation is an innovative medical device company that develops, manufactures, and sells the Omnipod system. This system provides continuous and tubeless automated insulin delivery for people with insulin-requiring diabetes.
How does Insulet Corporation generate revenue?+
Insulet operates a "razor and razorblade" business model, generating recurring revenue through the ongoing sale of disposable Omnipod pods via the pharmacy channel. Its U.S. Omnipod segment accounts for approximately 70% of total revenue, with International Omnipod contributing about 28%.
What are the key revenue growth assumptions in Insulet's financial model?+
The financial model for Insulet Corporation assumes a Revenue_Growth rate of 20% (0.2) for the forecast horizon. This reflects the company's high-growth trajectory, supported by factors like the expansion of its total addressable market.
What is the purpose of Insulet's equity valuation model?+
The model provides a comprehensive equity valuation and scenario analysis framework. Its purpose is to determine if Insulet's high-growth trajectory and operating margin expansion justify its premium market valuation amidst intensifying competition.
Can I download an Excel financial model for Insulet Corporation?+
Yes, an Excel financial model for Insulet Corporation (PODD) is available for download. This model offers a comprehensive framework for equity valuation and scenario analysis, forecasting through FY2030.
What is Insulet's competitive position in the automated insulin delivery market?+
Insulet holds a dominant competitive position as the global leader in tubeless insulin pumps, consistently ranking first in new customer starts. Key competitors include Tandem Diabetes Care, Medtronic, and Beta Bionics.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Medical Devices Company Financial Models
Browse another company in the same sector.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products.
Align Technology
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
Baxter International
Baxter International Inc.
Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Boston Scientific
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties.
Cooper Companies
The Cooper Companies, Inc.
Dexcom
Dexcom is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring systems that provide real-time glucose readings for people with diabetes, replacing traditional fingerstick testing.
Edwards Lifesciences
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease.
Explore more Healthcare financial model templates.
